Today: 8 November 2025
Subscribe
PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]
 ·  ·  ·  ·  · 

PACS Group (NYSE:PACS) Pops After NYSE Reprieve—Is the Nursing‑Home Giant Finally Turning the Corner? [Sep 26, 2025]

by
26 September 2025

Key facts (as of Sep 26, 2025)

  • Price/Move: $13.98 (+10.2% intraday); day range $12.69–$14.21; ~1.37M shares traded.
  • Today’s tape: Coverage notes shares +5% intraday during Friday’s session.  [1]
  • Latest corporate milestone: NYSE grants listing extension to Nov. 19, 2025 while PACS completes restatements and becomes current on SEC filings.  [2]
  • Operational snapshot (preliminary, 1H25): 316 facilities across 17 states; 88.9% occupancy vs. 78% industry; 64.6% of SNFs at 4–5‑star CMS QM; cash $294.2M.  [3]
  • Accounting update: PACS will restate 1H24 results—prelim. revenue overstatements of ~$15–17M (Q1) and ~$46–48M (Q2) tied to Medicare Part B recognition for certain services.  [4]
  • Governance: CFO Derick Apt resigned (Sep 2) after the audit committee found he accepted a “series of high‑value” gifts; co‑founder Mark Hancock named interim CFO (Sep 3).  [5]
  • Legal overhang: Multiple securities‑law investigations/class‑action efforts continue; Pomerantz LLP opened a fresh investigation Sep 24.  [6]
  • Street view (12‑mo targets): Average target ~$31–$35 (range $18–$50) across trackers (MarketBeat/Barron’s/Yahoo/TipRanks).  [7]

In‑depth report

What moved the stock this week

PACS rallied into the Sep 26 close with intraday gains reported by market trackers. The surge follows two mid‑September catalysts: (1) NYSE’s listing extension to Nov 19, 2025, giving the company runway to finish restatements and regain compliance; and (2) a series of governance actions, including a CFO change.  [8]

Management messaging turned incrementally constructive. CEO Jason Murray said PACS expects to report “record revenue and Adjusted EBITDA for the first six months of 2025” once filings are current. Interim Chief Compliance Officer Kathy Lauer added that PACS is “taking the right steps to best position the company” during its compliance overhaul.  [9]

Company snapshot

PACS Group is a post‑acute and senior‑living platform. As of June 30, 2025, subsidiaries operated 316 facilities with 32,208 SNF beds and 2,419 AL beds in 17 states. Occupancy was 88.9% (vs. industry ~78%), with 64.6% of SNFs scoring 4–5 stars on CMS Quality Measures—indicators management points to as proof of operating momentum. PACS also reported $294.2M cash on hand at June 30, 2025. All figures are preliminary and subject to the completion of restatements.  [10]

Where the risks came from (and what’s left to fix)

  • Revenue recognition & Medicare billing: On Jun 16, 2025, PACS said Part B respiratory and certain therapy services were incorrectly recognized as revenue in 1H24, resulting in prelim. overstatements of $15–17M (Q1) and $46–48M (Q2). The affected 2024 quarters “should no longer be relied upon,” and 10‑Q/10‑K filings for late‑2024 and 1Q25 remain outstanding.  [11]
  • Governance & leadership: On Sep 2, CFO Derick Apt resigned after the board concluded he had accepted a “series of high‑value items” from business associates—violating the code of conduct. Co‑founder Mark Hancockreturned as interim CFO on Sep 3. The board also disclosed a president‑level departure in August.  [12]
  • Listing compliance: NYSE granted another extension through Nov 19, 2025, keeping shares listed while PACS finishes restatements and becomes current with the SEC. Failure to meet that date risks delisting.  [13]
  • Litigation: Multiple law firms (e.g., Pomerantz) are investigating or have filed actions related to the restatements and disclosures; this keeps legal risk alive even if filings are completed.  [14]

What experts and primary sources are saying

  • CEO Jason Murray (Sep 11): “We expect to report record revenue and Adjusted EBITDA for the first six months of 2025 [once current on filings].”  [15]
  • Interim CCO Kathy Lauer: PACS is “taking the right steps” to enhance compliance and controls.  [16]
  • CFO.com (Sep 10) on the CFO change: the board said Apt accepted a “series of high‑value items”; Mark Hancock (co‑founder, prior CFO) was appointed interim CFO.  [17]

Street consensus, forecasts & how to read them

  • Targets: Aggregators show a $31–$35 average 12‑month target (high $50, low $18), implying >100% upside from ~$14. Sources vary on analyst counts due to coverage changes after the restatement announcement. Treat these with caution until audited financials are current.  [18]
  • Technical context: A tracker shows 50‑day SMA ~$11.36 and 200‑day SMA ~$11.08, so today’s move keeps shares above both medium‑term trend lines.  [19]

Operating pulse & industry backdrop

PACS’s preliminary metrics paint a picture of strong facility‑level performance (high occupancy, better‑than‑industry CMS quality scores) and balance‑sheet liquidity ($294.2M cash as of 6/30/25) that could support accretive acquisitions once filings normalize. That said, billing risk (Medicare Part B) and internal control enhancements remain priority workstreams through the NYSE deadline.  [20]

Timeline of recent events

  • Aug 15, 2025: President P.J. (Peter) Sanford resigns (consulting arrangement disclosed).  [21]
  • Sep 2–3, 2025: CFO Apt resigns; Hancock appointed interim CFO.  [22]
  • Sep 11, 2025: NYSE extension to Nov 19, 2025; management previews record 1H25 revenue & Adj. EBITDA; updated operating stats released.  [23]
  • Sep 24, 2025: Pomerantz begins new shareholder investigation.  [24]
  • Sep 26, 2025: Stock trades higher intraday; liquidity and trend remain in focus.  [25]

Valuation & scenarios (qualitative, given pending restatements)

  • Bull case: Restated financials filed on time; NYSE compliance restored; quality/occupancy metrics hold; Street re‑rates on cleaner earnings quality and continued tuck‑in acquisitions. Targets clustered around $31–$35 (high $50) become more credible if PACS validates record 1H25 Profitability.  [26]
  • Base case: Filings come through near deadline, but legal/oversight costs and Medicare billing guardrails compress margins; shares trade between trend and low‑end targets (e.g., $18–$31).  [27]
  • Bear case: Filing delays extend or findings worsen; NYSE compliance lapsed; litigation costs escalate; multiple compression toward single‑digit billions or delisting overhang weighs on liquidity.  [28]

What to watch next (date‑driven)

  1. Before Nov 19, 2025: Delivery of restated 1H24 financials and all delinquent 2024–1Q25/2Q25 reports to regain NYSE compliance.  [29]
  2. Management bench: Permanent CFO selection and any further board/committee changes.  [30]
  3. Legal docket: Progress in shareholder actions and any regulatory updates tied to Medicare Part B billing practices.  [31]
  4. Operating metrics: Occupancy, skilled‑mix, and acquisition cadence in 2H25; confirmation of “record” 1H25 revenue/Adj. EBITDA once filings resume.  [32]

Sources & further reading

  • Quote/metrics & NYSE extension (Sep 11): PACS IR / Business Wire press release with interim operating metrics and management quotes.  [33]
  • Restatement detail (Jun 16): PACS IR press release explaining recognition errors and preliminary overstatements.  [34]
  • CFO resignation (Sep 8 filing; Sep 10 coverage): PACS 8‑K and CFO.com/Healthcare Dive article on the code‑of‑conduct violations.  [35]
  • Share price/quote page: Yahoo Finance overview and analysis pages for PACS.  [36]
  • Analyst targets/consensus: MarketBeat forecast page; Barron’s research snapshot; TipRanks consensus.  [37]
  • Today’s trading color: MarketBeat intraday note.  [38]
  • Additional background: Reuters coverage of the 2024 IPO.  [39]

Quick take

PACS looks fundamentally busy and operationally resilient, but the investment case hinges on execution between now and Nov 19: finish the restatements, restore timely reporting, and steady governance. If PACS clears those hurdles, Street targets suggest ample upside; if not, listing and litigation risk remain the swing factors.

This report is for information only and not investment advice.

References

1. www.marketbeat.com, 2. www.businesswire.com, 3. www.businesswire.com, 4. ir.pacs.com, 5. ir.pacs.com, 6. www.globenewswire.com, 7. www.marketbeat.com, 8. www.marketbeat.com, 9. www.businesswire.com, 10. www.businesswire.com, 11. ir.pacs.com, 12. ir.pacs.com, 13. www.businesswire.com, 14. www.globenewswire.com, 15. www.businesswire.com, 16. www.businesswire.com, 17. www.cfo.com, 18. www.marketbeat.com, 19. www.marketbeat.com, 20. www.businesswire.com, 21. ir.pacs.com, 22. ir.pacs.com, 23. www.businesswire.com, 24. www.globenewswire.com, 25. www.marketbeat.com, 26. www.businesswire.com, 27. www.marketbeat.com, 28. www.businesswire.com, 29. www.businesswire.com, 30. ir.pacs.com, 31. www.globenewswire.com, 32. www.businesswire.com, 33. www.businesswire.com, 34. ir.pacs.com, 35. ir.pacs.com, 36. finance.yahoo.com, 37. www.marketbeat.com, 38. www.marketbeat.com, 39. www.reuters.com

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

  1. Samsung Confirms 10.7Gbps LPDDR6 and 14.8GB/s Gen5 PM9E1 SSD Ahead of CES 2026
  2. Brighter Than 10 Trillion Suns: Record Black Hole Flare 10 Billion Light‑Years Away
  3. ‘Landfall’ spyware abused Samsung zero‑day (CVE‑2025‑21042) to hack Galaxy phones for months — patched in April: What happened and how to stay safe
  4. Android Auto gets Gemini today (Nov 7, 2025): Live support begins rolling out, what’s new in v15.4, and what’s coming next

Stock Market Today

  • Enovis (ENOV) Valuation Persists as 12% Monthly Decline Highlights Growth Upside-Fair Value Roughly $49.67
    November 8, 2025, 8:18 AM EST. Enovis (ENOV) has fallen about 12% in the last month, with a year-to-date drop near 37% and a 12-month total return around -40%. Despite the slide, the stock trades around $28.06, with a leading fair value case of about $49.67, suggesting an undervalued setup. Proponents point to ongoing geographic expansion and the Lima shoulder portfolio integration as catalysts that could lift cross-selling, boost sales mix toward higher-growth, higher-margin segments, and drive further margin gains via operational synergies. But risks remain: integration challenges and potential delays in new technology launches could erode the optimistic earnings outlook and undermine the valuation gap.
  • Entravision Communications (NYSE:EVC) Announces $0.05 Dividend Amid Sustainability Questions
    November 8, 2025, 8:16 AM EST. Entravision Communications (NYSE:EVC) has reaffirmed a $0.05 per-share dividend payable on December 31, delivering a dividend yield around 6.9%. While the steady payout adds to investor income, questions loom over dividend sustainability: the company has been paying without profits and is not generating free cash flow, raising doubts about long-term viability of the distribution. Projections show a potential EPS rise of about 67.7% next year only if recent trends hold, but a return to profitability isn't guaranteed. As a result, management may face a choice between preserving the dividend or shoring up the balance sheet. Although the historic dividend has been relatively stable, the high payout ratio and earnings decline suggest caution for income-focused investors.
  • Dominion Energy Earnings Healthy, Yet Dilution Threatens EPS Growth
    November 8, 2025, 8:14 AM EST. Dominion Energy posted strong earnings, but the market reaction has been muted due to share dilution. Over the last year the company issued 103% more new shares, spreading net income across a larger base and suppressing EPS despite a 33% profit gain and a 164% three-year rise in net income. The contrast between higher profits and rising shares underscores that dilution is eating into per-share returns. Analysts' forward profitability estimates and interactive graphs exist, but investors should assess whether underlying earnings power exceeds statutory profit. In the end, EPS growth remains the key for long-term stock upside; if profits rise while EPS stalls, the share price may not follow. The piece also flags several risks and warning signs to consider.
  • Polestar Faces Nasdaq Bid-Price Rule Violation: Valuation in Focus as PSNY Trades Around $0.75
    November 8, 2025, 8:12 AM EST. Polestar Automotive UK (NasdaqGM:PSNY) faces a Nasdaq notice for trading below the $1.00 minimum bid price. Shares sit around $0.75, with a 1-year total return of about -39% and fading momentum. European expansion via a dealership partnership offers positive development, but investors still weigh valuation risk and funding dependence. Analysts' fair value targets hover near $1.00, flagging upside potential but tempered by persistent cash burn and potential shareholder dilution from new equity. The stock trades at a 0.7x price-to-sales multiple, well below the US Auto average (1.1x) and peers (1.7x), though a 0.4x fair valuation suggests the market may already price in risk. Bottom line: an entry point could exist if growth levers align, but regulatory risk and funding needs keep downside in play.
  • Expeditors International of Washington Announces $0.77 Dividend (EXPD) with Steady Payout Prospects
    November 8, 2025, 8:10 AM EST. Expeditors International of Washington (NYSE: EXPD) announced a dividend of $0.77 per share to be paid on December 15. The yield is modest at about 1.1%, but earnings comfortably cover the payout, supporting a likely sustainable payout ratio near 24% next year as EPS is forecast to rise by ~10.1%. The stock has a long history of steady distributions, growing from $0.72 to $1.54 annually since 2015, a rough 7.9% annual growth. Over five years, EPS growth has averaged around 11% per year, underpinning the dividend's durability and cash flow generation. While it looks like a solid long-term income stock, investors should note one identified warning sign to monitor.
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update
Previous Story

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Iran’s Rial Crisis Deepens: USD Soars Past 1.08 Million on Black Market Amid Sanctions Fears (قیمت دلار)
Next Story

Iran’s Rial Crisis Deepens: USD Soars Past 1.08 Million on Black Market Amid Sanctions Fears (قیمت دلار)

Related Articles

Go toTop